{"Clinical Trial ID": "NCT00101400", "Intervention": ["INTERVENTION 1:", "Sorafenib (Nexavar, BAY43-9006)", "Sorafenib 400 mg twice daily (p.i.d.)"], "Eligibility": ["Incorporation criteria:", "Age > 18", "Women with a prior diagnosis of breast cancer documented histologically", "Subjects with metastatic disease who have already received and failed at least one chemotherapy treatment for metastatic disease and who, in the case of ER/PgR +ve, have failed at least one hormonal treatment adjuvant", "Topics for which treatment with trastuzumab is not indicated, is no longer effective or refused by subjects", "Four weeks since the last cytotoxic chemotherapy or obvious signs of progress in hormonal treatment", "Subjects with at least one CT-measurable injury (digital tomography) or MRI (magnetic resonance imaging) according to modified WHO tumour response criteria", "Subjects with a performance status of 0, 1 or 2 from the Eastern Cooperative Oncology Group (ECOG)", "Adequate bone marrow, hepatic and renal function, as assessed by the following laboratory evaluations:", "Hemoglobin > 9.0 g/dl", "Absolute neutrophil count (NAC) > 1,500/mm3", "Number of platelets = 100 000/\u03bcl", "Total bilirubin = 1.5 x upper limit of normal.", "Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with hepatic cancer impairment)", "Amylase and lipase = 1.5 x upper limit of normal", "Serum creatinine rate = 3.0 x upper limit of normal", "Prothrombin time (PT) or International Standardized Report (INR) and Thromboplastin part time (PTT) < 1.5 x upper limit of normal (subjects receiving anti-coagulation therapy with an agent such as warfarin or heparin will be allowed to participate, provided there is no evidence of underlying anomaly in these parameters)", "Subjects who give their informed written consent prior to any selection procedure specific to the study, provided that the subject has the right to withdraw from the study at any time, without prejudice to", "Life expectancy of at least 12 weeks", "The signed informed consent must be obtained prior to any specific procedure under consideration.", "- Exclusion criteria:", "(except for cervical carcinomas in situ, adequately treated basal cell carcinomas, or superficial bladder tumours (Ta, Tis and T1) or other malignancies treated curatively > 2 years prior to entry)", "> New York Heart Association (NYHA) Class II", "- Cardiac arrhythmia requiring antiarrhythmia (excluding beta blockers or digoxins)", "\u2022 Active coronary artery disease or ischemia", "\u2022 Serious bacterial or fungal infections (> National Grade 2 Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3)", "\u2022 Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C", "In addition, the patient should not undergo acute steroid therapy or reduction (chronic steroid therapy is acceptable provided the dose is stable for 1 month before and after the X-ray screening study).", "Subjects with convulsive disorders requiring medication (such as steroids or antiepileptics)", "History of organ allograft", "The substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the results of the study", "A known or suspected allergy to the research officer", "Women of childbearing potential must undergo a negative pregnancy test within seven days of the start of the study. Women enrolled in this trial must use appropriate contraceptive measures during the trial.", "The excluded therapies include:", "In the case of cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks after entry into the study, mytomicin or nitrics should not be administered within 6 weeks of entry into the study.", "A major surgical procedure within 4 weeks prior to the start of the study", "Any bone marrow transplant or stem cell rescue within 4 months of the start of the study", "\u2022 Radiotherapy during the study or within 3 weeks after the start of the medicine", "The use of biological response modifiers, such as granulocyte-colony stimulating factor (G-CSF), within 3 weeks of entry into the study", "\u25cf Experimental pharmacotherapy outside of this trial during or within 30 days prior to the start of the study drug", "A concomitant treatment with ketoconazole, itraconazole, ritonavir or the use of grapefruit juice", "Prior use of Raf-Kinase inhibitors (RKI), methylethyl ketone inhibitors (MEK) or farnesyltransferase inhibitors", "Concomitant treatment or use of St John's wort", "\u2022 Prior use of bevacizumab and all other medicinal products targeting vascular endothelial growth factor (VEGF)/VEGF receptors"], "Results": ["Performance measures:", "Number of respondents (complete or partial)", "Number of subjects with metastatic breast cancer treated with a single BAY43-9006 agent who had the best overall response evaluated as a complete (RC) or partial (PR) response according to the modified World Health Organization (WHO) criteria for tumour response.", "Time limit: up to 30 days after completion of active therapy", "Results 1:", "Title of the arm/group: Sorafenib (Nexavar, BAY43-9006)", "Description of the arm/group: Sorafenib 400 mg twice daily (p.i.d.)", "Total number of participants analysed: 54", "Type of measurement: Number", "Unit of measure: Participants Full response (CR): 0", "Partial response (PR): 1", "Stable disease (SD): 20", "Progressive diseases (PD): 31", "Not evaluated: 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/54 (40.74 per cent)", "Hemoglobin * 1/54 (1.85%)", "Coagulation - Other * 1/54 (1.85%)", "Superventricular arrhythmia, supraventricular tachycardia * 1/54 (1.85%)", "* 2/54 (3.70 per cent)", "Anorexia * 1/54 (1.85%)", "Ascites * 2/54 (3.70%)", "Nausea * 2/54 (3.70%)", "Perforation, IG, Colon * 1/54 (1.85%)", "Vomiting * 1/54 (1.85%)"]}